相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
Yanling Wu et al.
MOLECULAR THERAPY (2022)
Antibody mutations favoring pH-dependent binding in solid tumor microenvironments: Insights from large-scale structure-based calculations
Wanlei Wei et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2022)
Antibodies to watch in 2021
Helene Kaplon et al.
MABS (2021)
Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase In Vivo Efficacy
Jose F. Ponte et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Structure-based engineering of pH-dependent antibody binding for selective targeting of solid-tumor microenvironment
Traian Sulea et al.
MABS (2020)
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
Guolan Lu et al.
CLINICAL CANCER RESEARCH (2020)
Preclinical murine tumor models: a structural and functional perspective
Marion V. Guerin et al.
ELIFE (2020)
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
Tania Crombet Ramos et al.
FRONTIERS IN ONCOLOGY (2020)
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Wen-Qi Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates
Guolan Lu et al.
NATURE COMMUNICATIONS (2020)
Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy
Jeffrey C. Kang et al.
NATURE BIOTECHNOLOGY (2019)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston et al.
NATURE (2019)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival
Cornelius Cilliers et al.
CANCER RESEARCH (2018)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
A potent human neutralizing antibody Fc-dependently reduces established HBV infections
Dan Li et al.
ELIFE (2017)
EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics
Daniel M. Freed et al.
CELL (2017)
Tumour acidosis: from the passenger to the driver's seat
Cyril Corbet et al.
NATURE REVIEWS CANCER (2017)
ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation
Jinwoo Leem et al.
MABS (2016)
ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Edward B. Reilly et al.
MOLECULAR CANCER THERAPEUTICS (2015)
AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Kevin J. Hamblett et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Cetuximab-mediated Tumor Regression Depends on Innate and Adaptive Immune Responses
Xuanming Yang et al.
MOLECULAR THERAPY (2013)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9
Javier Chaparro-Riggers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
Daniel J. Freeman et al.
MOLECULAR CANCER (2012)
Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
Greta Garrido et al.
CANCER BIOLOGY & THERAPY (2011)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
Tomoyuki Igawa et al.
NATURE BIOTECHNOLOGY (2010)
The safety and side effects of monoclonal antibodies
Trevor T. Hansel et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Jamie B. Spangler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Antibodies specifically targeting a locally misfolded region of tumor associated EGFR
Thomas P. J. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Jose Baselga et al.
NATURE REVIEWS CANCER (2009)
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Greg M. Thurber et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
The biological properties of cetuximab
Bruno Vincenzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
EGFR family: Structure physiology signalling and therapeutic targets
Antony W. Burgess
GROWTH FACTORS (2008)
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
Margaret E. Ackerman et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Hideharu Kimura et al.
CANCER SCIENCE (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Humanized mice in translational biomedical research
Leonard D. Shultz et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action
Jeroen J. Lannnerts van Bueren et al.
CANCER RESEARCH (2006)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Why do cancers have high aerobic glycolysis?
RA Gatenby et al.
NATURE REVIEWS CANCER (2004)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
AA Jungbluth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
H Ogiso et al.
CELL (2002)
Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching
CA Sarkar et al.
NATURE BIOTECHNOLOGY (2002)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)